Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery
Kidney FailureRenal FailureThe purpose of this study is to evaluate the potential of erythropoietin in reducing risk and degree of acute kidney injury after cardiac surgery.
Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae...
End Stage Renal DiseaseAV Fistula1 moreThe SAVE Study will evaluate the safety and efficacy of the Venous Window Needle Guide in achieving access of a deep, un-cannulatable arteriovenous fistula to complete hemodialysis as prescribed.
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma...
Multiple MyelomaRenal ImpairmentThe purpose of this study is to determine the pharmacokinetics (PK) and safety for the combination of pomalidomide (POM) + low-dose dexamethasone (LD- DEX) in subjects with relapsed or refractory Multiple Myeloma (RRMM) and impaired renal function.
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine...
GoutHyperuricemia3 moreTo evaluate the overall safety and tolerability of ulodesine when combined with allopurinol in subjects with moderate renal insufficiency.
Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure
Acute Renal FailureThe purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute renal failure (ARF).
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment...
Renal ImpairmentThe purpose of this study is to determine the effect of febuxostat, once daily (QD) or twice daily (BID), on renal function in gout patients with elevated serum urate levels and who have moderate to severe renal impairment.
Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients
Renal ImpairmentDiabetesThis study assess the pharmacokinetics of vildagliptin in mild, moderate and severe renal impaired patients
Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From...
Renal FailureThis is 2-armed parallel group, prospective, randomized, open-label, multicenter Phase 3 controlled trial to establish the efficacy and safety of conversion from maintenance immunosuppressive therapy with Prograf® capsules (tacrolimus, Astellas Pharma US, Inc., Deerfield, IL) twice daily to maintenance immunotherapy with LCP Tacro™ tablets (tacrolimus, LifeCycle Pharma A/S, Hoersholm, Denmark) once daily for the prevention of acute allograft rejection in stable adult kidney transplant patients. Patients on a stable dose of Prograf® will be randomly assigned to be converted from Prograf® twice daily to LCP Tacro™ once daily or to remain on maintenance therapy with Prograf® twice daily. Patients entering the study will be treated with assigned study drug and followed for one year for patient survival and the incidence of graft rejection or graft loss.
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
Renal InsufficiencyThe purpose of this study is to determine a preventative dose of study drug, Arixtra® for patients with kidney disease. We will measure the blood levels of Arixtra® in patients with kidney disease and develop guidelines for dosing.
Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)...
DyslipidemiaThis study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib in subjects with impaired renal function and healthy matched control subjects.